- Home
- FLYE vs RDHL Comparison
FLYE vs RDHL Comparison
Compare FLYE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLYE | RDHL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.3M |
| IPO Year | 2024 | 2012 |
Fundamental Metrics
Financial Performance| Metric | FLYE | RDHL |
|---|---|---|
| Price | $1.43 | $0.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 2.5M |
| Earning Date | 04-21-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,063,357.00 | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.49 |
| 52 Week High | $21.80 | $2.61 |
Technical Indicators
Market Signals| Indicator | FLYE | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 33.94 |
| Support Level | $1.32 | N/A |
| Resistance Level | $1.92 | $1.07 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 19.82 | 6.49 |
Price Performance
Historical ComparisonAbout FLYE Fly-E Group Inc.
Fly-E Group Inc is principally engaged in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand. The Company encourages the adoption of eco-friendly transportation for active lifestyles.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.